Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
mark a milestone for the business and lead to significant revenue growth. The risk with many biotech stocks is not knowing if they will obtain approval for a key treatment, or if that approval might come with an asterisk and only cover certain aspects of an illness or condition. Sarepta Therapeutics (NASDAQ: SRPT) stock has been flying of late, as the company got some great news from the FDA that has the potential to be a game changer for its business. Investors are bullish on the developments. Here's a look at the details and what they mean for the company. Sarepta obtains label expansion for its therapy Last year, the FDA granted accelerated approval for Sarepta's gene therapy treatment, Elevidys, as a treatment for Duchenne muscular dystrophy (DMD) in children between the ages of 4 and 5. That was bittersweet for investors because while it was an approval, its scope was narrow, and the company was hoping for a broader indication. But last month, the FDA expanded the use of
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- After a Big Win, Is Sarepta Therapeutics Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Best Momentum Stocks to Buy for July 3rd [Yahoo! Finance]Yahoo! Finance
- 1 Soaring Growth Stock to Buy and Hold for 10 Years [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $205.00 price target on the stock.MarketBeat
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
SRPT
Earnings
- 5/1/24 - Beat
SRPT
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- SRPT's page on the SEC website